|
Evaluating the Prevalence of Plasminogen Activator Inhibitor-1 Gene Polymorphism in Patients with Thyroid Tumors from North West of Iran
|
Mahdieh Younesi1   , Mohammadali Hosseinpour Feizi * 2, Nasser Pouladi3 |
1- Dept of Animal Biology, Faculty of Natural Sciences, Tabriz University,Tabriz, Iran
2- Dept of Animal Biology, Faculty of Natural Sciences, Tabriz University,Tabriz, Iran , pourfeizi@eastp.ir
3- Dept of Biology, Faculty of Sciences, Azarbaijan Shahid Madani University, Tabriz, Iran |
|
|
Abstract: (4961 Views) |
Introduction: Association of PAI-1 polymorphisms with the increased risk of various malignancies has been shown in numerous studies. Therefore, the aim of the current study is to evaluate the prevalence of PAI-1 4G/5G polymorphism in patients with thyroid tumors from North West of Iran.
Materials & methods: Ninety patients with thyroid tumors and 180 healthy controls were selected from North West of Iran. DNA was extracted from peripheral blood samples and 4G/5G polymorphism of the PAI-1 gene was evaluated by polymerase chain reaction using specific primers.
Findings: Genotype distribution between patients was (4G/4G=13.33%, 4G/5G=63.33% and 5G/5G=23.33%) and controls (4G/4G=17.22%, 4G/5G=67.22% and 5G/5G=15.55%). Additionally, the frequencies of the 4G and 5G alleles between patients were (45% and 55%) and control group (50.83% and 49.16%).
Discussion & conclusions: Results indicate that the genotypic and allelic frequencies of PAI-1 4G/5G polymorphism showed no significant difference between patients with thyroid tumors and control individuals in this cohort. |
|
| Keywords: Polymorphism, Plasminogen activation system, Thyroid tumors |
|
|
Full-Text [PDF 353 kb]
(1880 Downloads)
|
Type of Study: Research |
Received: 2015/12/16 | Accepted: 2016/02/14 | Published: 2017/07/18
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
